Stock TLX TELIX PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Delayed Australian S.E.
Other stock markets
 11:22:58 2024-04-25 pm EDT 		5-day change 1st Jan Change
14.87 AUD -0.07% Intraday chart for Telix Pharmaceuticals Limited +9.33% +47.62%
Apr. 18 Jarden Adjusts Telix Pharmaceuticals Price Target to AU$13.52 from AU$13.27, Keeps at Buy MT
Apr. 17 Telix Pharmaceuticals Limited Reports Unaudited Revenue Results for the First Quarter Ended 31 March 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Telix - Notice of Annual General Meeting 2024
AQ
Jarden Adjusts Telix Pharmaceuticals Price Target to AU$13.52 from AU$13.27, Keeps at Buy
MT
Q1 2024 Revenue and Business Update
AQ
Telix Pharmaceuticals Limited Reports Unaudited Revenue Results for the First Quarter Ended 31 March 2024
CI
Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024
CI
Telix Pharmaceuticals Logs Nearly $115 Million Revenue in Q1
MT
Telix Pharmaceuticals Secures US FDA Fast-Track Designation for Brain Cancer Imaging Product
MT
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
AQ
Telix Pharmaceuticals Limited Announces FDA Fast Track Designation for TLX101-CDx
CI
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
BU
Telix Pharmaceuticals Completes Acquisition of Canadian Firm ARTMS
MT
Telix Pharmaceuticals Limited completed the acquisition of ARTMS, INC.
CI
Telix Pharmaceuticals Completes Acquisition of IsoTherapeutics Group
MT
Telix Pharmaceuticals Limited completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.
CI
Telix Pharmaceuticals - World First Use of Lightpoint's SENSEI Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
AQ
World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
AQ
Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent
CI
QDOSE Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy
AQ
QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy
AQ
Telix Pharmaceuticals Appoints Group COO; Shares Down 4%
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TLX Stock
  4. News Telix Pharmaceuticals Limited